Longitudinal analysis of PD-L1 expression in patients with relapsed NSCLC
BackgroundThe use and approval of immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) depends on PD-L1 expression in the tumor tissue. Nevertheless, PD-L1 often fails to predict response to treatment. One possible explanation could be a change in PD-L1 expression dur...
Saved in:
Published in | Journal for immunotherapy of cancer Vol. 12; no. 4; p. e008592 |
---|---|
Main Authors | , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
BMJ Publishing Group Ltd
11.04.2024
BMJ Publishing Group LTD BMJ Publishing Group |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | BackgroundThe use and approval of immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) depends on PD-L1 expression in the tumor tissue. Nevertheless, PD-L1 often fails to predict response to treatment. One possible explanation could be a change in PD-L1 expression during the course of the disease and the neglect of reassessment. The purpose of this study was a longitudinal analysis of PD-L1 expression in patients with relapsed NSCLC.MethodsWe retrospectively analyzed PD-L1 expression in patients with early-stage NSCLC and subsequent relapse in preoperative samples, matched surgical specimens and biopsy samples of disease recurrence. Ventana PD-L1 (SP263) immunohistochemistry assay was used for all samples. PD-L1 expression was scored based on clinically relevant groups (0%, 1%–49%, and ≥50%). The primary endpoint was the change in PD-L1 score group between preoperative samples, matched surgical specimens and relapsed tumor tissue.Results395 consecutive patients with stages I–III NSCLC and 136 (34%) patients with a subsequent relapse were identified. For 87 patients at least two specimens for comparison of PD-L1 expression between early stage and relapsed disease were available. In 72 cases, a longitudinal analysis between preoperative biopsy, the surgically resected specimen and biopsy of disease recurrence was feasible. When comparing preoperative and matched surgical specimens, a treatment-relevant conversion of PD-L1 expression group was found in 25 patients (34.7%). Neoadjuvant treatment showed no significant effect on PD-L1 alteration (p=0.39). In 32 (36.8%) out of 87 cases, a change in PD-L1 group was observed when biopsies of disease relapse were compared with early-stage disease. Adjuvant treatment was not significantly associated with a change in PD-L1 expression (p=0.53). 39 patients (54.2%) showed at least 1 change into a different PD-L1 score group during the course of disease. 14 patients (19.4%) changed the PD-L1 score group twice, 5 (6.9%) of them being found in all different score groups.ConclusionPD-L1 expression shows dynamic changes during the course of disease. There is an urgent need for consensus guidelines to define a PD-L1 testing strategy including time points of reassessment, the number of biopsies to be obtained and judgment of surgical specimens. |
---|---|
AbstractList | BackgroundThe use and approval of immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) depends on PD-L1 expression in the tumor tissue. Nevertheless, PD-L1 often fails to predict response to treatment. One possible explanation could be a change in PD-L1 expression during the course of the disease and the neglect of reassessment. The purpose of this study was a longitudinal analysis of PD-L1 expression in patients with relapsed NSCLC.MethodsWe retrospectively analyzed PD-L1 expression in patients with early-stage NSCLC and subsequent relapse in preoperative samples, matched surgical specimens and biopsy samples of disease recurrence. Ventana PD-L1 (SP263) immunohistochemistry assay was used for all samples. PD-L1 expression was scored based on clinically relevant groups (0%, 1%–49%, and ≥50%). The primary endpoint was the change in PD-L1 score group between preoperative samples, matched surgical specimens and relapsed tumor tissue.Results395 consecutive patients with stages I–III NSCLC and 136 (34%) patients with a subsequent relapse were identified. For 87 patients at least two specimens for comparison of PD-L1 expression between early stage and relapsed disease were available. In 72 cases, a longitudinal analysis between preoperative biopsy, the surgically resected specimen and biopsy of disease recurrence was feasible. When comparing preoperative and matched surgical specimens, a treatment-relevant conversion of PD-L1 expression group was found in 25 patients (34.7%). Neoadjuvant treatment showed no significant effect on PD-L1 alteration (p=0.39). In 32 (36.8%) out of 87 cases, a change in PD-L1 group was observed when biopsies of disease relapse were compared with early-stage disease. Adjuvant treatment was not significantly associated with a change in PD-L1 expression (p=0.53). 39 patients (54.2%) showed at least 1 change into a different PD-L1 score group during the course of disease. 14 patients (19.4%) changed the PD-L1 score group twice, 5 (6.9%) of them being found in all different score groups.ConclusionPD-L1 expression shows dynamic changes during the course of disease. There is an urgent need for consensus guidelines to define a PD-L1 testing strategy including time points of reassessment, the number of biopsies to be obtained and judgment of surgical specimens. Background The use and approval of immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) depends on PD-L1 expression in the tumor tissue. Nevertheless, PD-L1 often fails to predict response to treatment. One possible explanation could be a change in PD-L1 expression during the course of the disease and the neglect of reassessment. The purpose of this study was a longitudinal analysis of PD-L1 expression in patients with relapsed NSCLC.Methods We retrospectively analyzed PD-L1 expression in patients with early-stage NSCLC and subsequent relapse in preoperative samples, matched surgical specimens and biopsy samples of disease recurrence. Ventana PD-L1 (SP263) immunohistochemistry assay was used for all samples. PD-L1 expression was scored based on clinically relevant groups (0%, 1%–49%, and ≥50%). The primary endpoint was the change in PD-L1 score group between preoperative samples, matched surgical specimens and relapsed tumor tissue.Results 395 consecutive patients with stages I–III NSCLC and 136 (34%) patients with a subsequent relapse were identified. For 87 patients at least two specimens for comparison of PD-L1 expression between early stage and relapsed disease were available. In 72 cases, a longitudinal analysis between preoperative biopsy, the surgically resected specimen and biopsy of disease recurrence was feasible. When comparing preoperative and matched surgical specimens, a treatment-relevant conversion of PD-L1 expression group was found in 25 patients (34.7%). Neoadjuvant treatment showed no significant effect on PD-L1 alteration (p=0.39). In 32 (36.8%) out of 87 cases, a change in PD-L1 group was observed when biopsies of disease relapse were compared with early-stage disease. Adjuvant treatment was not significantly associated with a change in PD-L1 expression (p=0.53). 39 patients (54.2%) showed at least 1 change into a different PD-L1 score group during the course of disease. 14 patients (19.4%) changed the PD-L1 score group twice, 5 (6.9%) of them being found in all different score groups.Conclusion PD-L1 expression shows dynamic changes during the course of disease. There is an urgent need for consensus guidelines to define a PD-L1 testing strategy including time points of reassessment, the number of biopsies to be obtained and judgment of surgical specimens. Background The use and approval of immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) depends on PD-L1 expression in the tumor tissue. Nevertheless, PD-L1 often fails to predict response to treatment. One possible explanation could be a change in PD-L1 expression during the course of the disease and the neglect of reassessment. The purpose of this study was a longitudinal analysis of PD-L1 expression in patients with relapsed NSCLC. Methods We retrospectively analyzed PD-L1 expression in patients with early-stage NSCLC and subsequent relapse in preoperative samples, matched surgical specimens and biopsy samples of disease recurrence. Ventana PD-L1 (SP263) immunohistochemistry assay was used for all samples. PD-L1 expression was scored based on clinically relevant groups (0%, 1%–49%, and ≥50%). The primary endpoint was the change in PD-L1 score group between preoperative samples, matched surgical specimens and relapsed tumor tissue. Results 395 consecutive patients with stages I–III NSCLC and 136 (34%) patients with a subsequent relapse were identified. For 87 patients at least two specimens for comparison of PD-L1 expression between early stage and relapsed disease were available. In 72 cases, a longitudinal analysis between preoperative biopsy, the surgically resected specimen and biopsy of disease recurrence was feasible. When comparing preoperative and matched surgical specimens, a treatment-relevant conversion of PD-L1 expression group was found in 25 patients (34.7%). Neoadjuvant treatment showed no significant effect on PD-L1 alteration (p=0.39). In 32 (36.8%) out of 87 cases, a change in PD-L1 group was observed when biopsies of disease relapse were compared with early-stage disease. Adjuvant treatment was not significantly associated with a change in PD-L1 expression (p=0.53). 39 patients (54.2%) showed at least 1 change into a different PD-L1 score group during the course of disease. 14 patients (19.4%) changed the PD-L1 score group twice, 5 (6.9%) of them being found in all different score groups. Conclusion PD-L1 expression shows dynamic changes during the course of disease. There is an urgent need for consensus guidelines to define a PD-L1 testing strategy including time points of reassessment, the number of biopsies to be obtained and judgment of surgical specimens. The use and approval of immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) depends on PD-L1 expression in the tumor tissue. Nevertheless, PD-L1 often fails to predict response to treatment. One possible explanation could be a change in PD-L1 expression during the course of the disease and the neglect of reassessment. The purpose of this study was a longitudinal analysis of PD-L1 expression in patients with relapsed NSCLC. We retrospectively analyzed PD-L1 expression in patients with early-stage NSCLC and subsequent relapse in preoperative samples, matched surgical specimens and biopsy samples of disease recurrence. Ventana PD-L1 (SP263) immunohistochemistry assay was used for all samples. PD-L1 expression was scored based on clinically relevant groups (0%, 1%-49%, and ≥50%). The primary endpoint was the change in PD-L1 score group between preoperative samples, matched surgical specimens and relapsed tumor tissue. 395 consecutive patients with stages I-III NSCLC and 136 (34%) patients with a subsequent relapse were identified. For 87 patients at least two specimens for comparison of PD-L1 expression between early stage and relapsed disease were available. In 72 cases, a longitudinal analysis between preoperative biopsy, the surgically resected specimen and biopsy of disease recurrence was feasible. When comparing preoperative and matched surgical specimens, a treatment-relevant conversion of PD-L1 expression group was found in 25 patients (34.7%). Neoadjuvant treatment showed no significant effect on PD-L1 alteration (p=0.39). In 32 (36.8%) out of 87 cases, a change in PD-L1 group was observed when biopsies of disease relapse were compared with early-stage disease. Adjuvant treatment was not significantly associated with a change in PD-L1 expression (p=0.53). 39 patients (54.2%) showed at least 1 change into a different PD-L1 score group during the course of disease. 14 patients (19.4%) changed the PD-L1 score group twice, 5 (6.9%) of them being found in all different score groups. PD-L1 expression shows dynamic changes during the course of disease. There is an urgent need for consensus guidelines to define a PD-L1 testing strategy including time points of reassessment, the number of biopsies to be obtained and judgment of surgical specimens. |
Author | Wurm, Robert Brcic, Luka Terbuch, Angelika Lindenmann, Jörg Kalson, Lipika Absenger, Gudrun John, Nikolaus Sassmann, Teresa Fediuk, Melanie Posch, Florian Zacharias, Martin Schlintl, Verena Douschan, Philipp Jost, Philipp J |
Author_xml | – sequence: 1 givenname: Nikolaus surname: John fullname: John, Nikolaus organization: Division of Pulmonology, Department of Internal Medicine, Medical University of Graz, Graz, Austria – sequence: 2 givenname: Verena surname: Schlintl fullname: Schlintl, Verena organization: Division of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria – sequence: 3 givenname: Teresa surname: Sassmann fullname: Sassmann, Teresa organization: Division of Pulmonology, Department of Internal Medicine, Medical University of Graz, Graz, Austria – sequence: 4 givenname: Jörg surname: Lindenmann fullname: Lindenmann, Jörg organization: Division of Thoracic Surgery, Department of Surgery, Medical University of Graz, Graz, Austria – sequence: 5 givenname: Melanie surname: Fediuk fullname: Fediuk, Melanie organization: Division of Thoracic Surgery, Department of Surgery, Medical University of Graz, Graz, Austria – sequence: 6 givenname: Robert surname: Wurm fullname: Wurm, Robert organization: Division of Pulmonology, Department of Internal Medicine, Medical University of Graz, Graz, Austria – sequence: 7 givenname: Philipp surname: Douschan fullname: Douschan, Philipp organization: Department of Internal Medicine, Marburg Lung Center, Giessen, Germany – sequence: 8 givenname: Martin surname: Zacharias fullname: Zacharias, Martin organization: Diagnostic and Research Institute of Pathology, Medical University of Graz, Graz, Austria – sequence: 9 givenname: Lipika surname: Kalson fullname: Kalson, Lipika organization: Diagnostic and Research Institute of Pathology, Medical University of Graz, Graz, Austria – sequence: 10 givenname: Florian surname: Posch fullname: Posch, Florian organization: Division of Hematology, Department of Internal Medicine, Medical University of Graz, Graz, Austria – sequence: 11 givenname: Gudrun surname: Absenger fullname: Absenger, Gudrun organization: Division of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria – sequence: 12 givenname: Luka surname: Brcic fullname: Brcic, Luka email: luka.brcic@medunigraz.at organization: Diagnostic and Research Institute of Pathology, Medical University of Graz, Graz, Austria – sequence: 13 givenname: Philipp J surname: Jost fullname: Jost, Philipp J organization: BioTechMed-Graz Office, Graz, Austria – sequence: 14 givenname: Angelika orcidid: 0000-0003-2918-1370 surname: Terbuch fullname: Terbuch, Angelika email: angelika.terbuch@medunigraz.at organization: Division of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38604811$$D View this record in MEDLINE/PubMed |
BookMark | eNp1kUtv1TAQRi1UREvpnhWyxIZFA-NnnCW65XGlCJCAteXYTnGUGwc7Uem_x5eUgpDY2NbozGePz2N0MsXJI_SUwEtCmHw1hMVWFCirAJRo6AN0RkGQinAqT_46n6KLnAcAIMCYUuoROmVKAleEnKF9G6frsKwuTGbEpiy3OWQce_zpqmoJ9j_m5HMOccJhwrNZgp-WjG_C8g0nP5o5e4c_fN61uyfoYW_G7C_u9nP09e2bL7v3Vfvx3X73uq06TsVSESqdMtDxRjCpBGGC1U5wyrjiQJU11vYWpPc18Q5qbgrnBHGFF4awnp2j_Zbrohn0nMLBpFsdTdC_CjFda5OWYEev646JugHheyo4QFemhkYSa5x0jbO0ZL3YsuYUv68-L_oQsvXjaCYf16wZMMWpqkEW9Pk_6BDXVP7rSHEiGsY4FAo2yqaYc_L9_QMJ6KM1fbSmj9b0Zq20PLsLXruDd_cNvx0V4HIDusPw59L_5v0EJL6ecQ |
Cites_doi | 10.1093/annonc/mdy041 10.1200/JCO.18.00149 10.1093/annonc/mdv489 10.3389/fimmu.2020.598877 10.1007/s00432-018-2642-4 10.1038/nri3845 10.1371/journal.pone.0130142 10.1016/S1470-2045(20)30641-0 10.1371/journal.pone.0123410 10.1016/j.jtho.2020.11.025 10.1038/srep20090 10.1056/NEJMoa1613493 10.1038/s41577-019-0218-4 10.1136/jitc-2022-006311 10.18632/oncotarget.22690 10.1056/NEJMoa1709937 10.1038/bjc.2015.101 10.1038/s41379-022-01139-y 10.1016/j.lungcan.2017.08.005 10.1200/JCO.19.03136 10.1016/j.lungcan.2019.06.005 10.21873/anticanres.12662 10.1016/j.lungcan.2020.08.020 10.1111/his.13750 10.1016/S1470-2045(16)30406-5 10.1016/j.ejca.2014.01.018 10.1056/NEJMoa1810865 10.3322/caac.21660 10.1056/NEJMoa1716948 10.1016/S0140-6736(21)02098-5 10.1172/JCI67313 10.18632/oncotarget.22582 10.1016/j.canlet.2008.10.028 10.1016/j.lungcan.2019.07.027 10.1016/j.pathol.2020.10.007 10.1056/NEJMoa1606774 10.1016/j.cllc.2017.04.014 10.1056/NEJMoa1809697 10.1093/annonc/mdy292.040 10.21037/jtd.2019.12.24 10.1016/S1470-2045(16)30498-3 10.1158/1538-7445.AM2018-CT075 |
ContentType | Journal Article |
Copyright | Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. 2024 Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
Copyright_xml | – notice: Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. – notice: 2024 Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
DBID | 9YT ACMMV CGR CUY CVF ECM EIF NPM AAYXX CITATION 3V. 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. M0S M1P PIMPY PQEST PQQKQ PQUKI PRINS 7X8 DOA |
DOI | 10.1136/jitc-2023-008592 |
DatabaseName | BMJ Open Access Journals BMJ Journals:Open Access Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central ProQuest Central Essentials AUTh Library subscriptions: ProQuest Central ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) Publicly Available Content Database ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic DOAJ Directory of Open Access Journals |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Publicly Available Content Database ProQuest Central Essentials ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete Health Research Premium Collection ProQuest Medical Library ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest Central Korea ProQuest One Academic ProQuest Medical Library (Alumni) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic Publicly Available Content Database CrossRef MEDLINE |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: ACMMV name: BMJ Journals:Open Access url: https://journals.bmj.com/ sourceTypes: Publisher – sequence: 5 dbid: 7X7 name: Health & Medical Collection url: https://search.proquest.com/healthcomplete sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 2051-1426 |
ExternalDocumentID | oai_doaj_org_article_7b357905ef25400b8600961cad6d9dc2 10_1136_jitc_2023_008592 38604811 ttps://jitc.bmj.com/content/12/4/e008592.full |
Genre | Journal Article |
GroupedDBID | -A0 3V. 4.4 53G 5VS 7X7 88E 8FI 8FJ 9YT ABDBF ABUWG ACGFS ACMMV ADBBV ADINQ ADRAZ AFGXO AFKRA AHBYD AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AOIJS ASPBG AVWKF BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C24 C6C CCPQU DIK FYUFA GROUPED_DOAJ HMCUK HYE IAO IHR IHW INH INR ITC KQ8 M1P M48 M~E OK1 PIMPY PQQKQ PROAC PSQYO RBZ RMJ RPM RSV SOJ UKHRP CGR CUY CVF EBS ECM EIF NPM AAYXX ACRMQ ADUKV AHSBF CITATION EJD H13 ROL 7XB 8FK AZQEC DWQXO K9. PQEST PQUKI PRINS 7X8 |
ID | FETCH-LOGICAL-b425t-126d8a0b495368513537d5423484028caccfc06ee71ed074a953d51d4955a13f3 |
IEDL.DBID | DOA |
ISSN | 2051-1426 |
IngestDate | Tue Oct 22 15:14:53 EDT 2024 Sat Oct 26 05:39:29 EDT 2024 Sat Oct 26 06:50:11 EDT 2024 Thu Sep 12 18:39:20 EDT 2024 Thu Oct 24 09:57:17 EDT 2024 Wed Aug 21 00:05:48 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 4 |
Keywords | Immune Checkpoint Inhibitor Biomarker Lung Cancer |
Language | English |
License | This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/. Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-b425t-126d8a0b495368513537d5423484028caccfc06ee71ed074a953d51d4955a13f3 |
Notes | Original research ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0003-2918-1370 |
OpenAccessLink | https://doaj.org/article/7b357905ef25400b8600961cad6d9dc2 |
PMID | 38604811 |
PQID | 3041593340 |
PQPubID | 2040222 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_7b357905ef25400b8600961cad6d9dc2 proquest_miscellaneous_3038428706 proquest_journals_3041593340 crossref_primary_10_1136_jitc_2023_008592 pubmed_primary_38604811 bmj_journals_10_1136_jitc_2023_008592 |
PublicationCentury | 2000 |
PublicationDate | 2024-04-11 |
PublicationDateYYYYMMDD | 2024-04-11 |
PublicationDate_xml | – month: 04 year: 2024 text: 2024-04-11 day: 11 |
PublicationDecade | 2020 |
PublicationPlace | England |
PublicationPlace_xml | – name: England – name: London |
PublicationTitle | Journal for immunotherapy of cancer |
PublicationTitleAbbrev | J Immunother Cancer |
PublicationTitleAlternate | J Immunother Cancer |
PublicationYear | 2024 |
Publisher | BMJ Publishing Group Ltd BMJ Publishing Group LTD BMJ Publishing Group |
Publisher_xml | – name: BMJ Publishing Group Ltd – name: BMJ Publishing Group LTD – name: BMJ Publishing Group |
References | Haragan, Field, Davies (R33) 2019; 134 Casadevall, Clavé, Taus (R15) 2017; 18 Antonia, Villegas, Daniel (R29) 2017; 377 Langer, Gadgeel, Borghaei (R21) 2016; 17 Saito, Horiuchi, Morooka (R16) 2019; 11 Abiko, Matsumura, Hamanishi (R39) 2015; 112 Liang, Yang, Fu (R14) 2009; 276 Paz-Ares, Luft, Vicente (R25) 2018; 379 Bassanelli, Sioletic, Martini (R32) 2018; 38 Sheng, Fang, Yu (R9) 2016; 6 Terra, Mansfield, Vrana (R35) 2019; 74 Gowrishankar, Gunatilake, Gallagher (R36) 2015; 10 Bai, Gao, Li (R11) 2017; 8 Ilie, Long-Mira, Bence (R34) 2016; 27 Jardim, Murugesan, Elvin (R12) 2023; 11 Reck, Rodríguez-Abreu, Robinson (R4) 2019; 37 Lacour, Lee, Rulle (R38) 2018; 29 Kalbasi, Ribas (R42) 2020; 20 Socinski, Jotte, Cappuzzo (R30) 2018; 378 Antonia, Villegas, Daniel (R23) 2018; 379 Gadgeel, Rodríguez-Abreu, Speranza (R3) 2020; 38 Hack, Zhu, Wang (R43) 2020; 11 Frank, Bødtger, Høegholm (R37) 2020; 149 Kim, Hong, Kim (R6) 2017; 8 Yang, Lin, Chang (R13) 2014; 50 Choe, Cha, Kim (R7) 2019; 136 Carbone, Reck, Paz-Ares (R26) 2017; 376 Rojkó, Reiniger, Téglási (R41) 2018; 144 Nishio, Barlesi, West (R31) 2021; 16 Deng, Liang, Burnette (R40) 2014; 124 Reck, Rodríguez-Abreu, Robinson (R20) 2016; 375 Gandhi, Rodgríguez-Abreu, Gadgeel (R24) 2018; 78 Gibney, Weiner, Atkins (R5) 2016; 17 Zens, Bello, Scherz (R8) 2022; 35 Brody, Zhang, Ballas (R17) 2017; 112 Felip, Altorki, Zhou (R22) 2021; 398 Paz-Ares, Ciuleanu, Cobo (R27) 2021; 22 Zitvogel, Galluzzi, Kepp (R10) 2015; 15 Sung, Ferlay, Siegel (R1) 2021; 71 Vokes, Ready, Felip (R28) 2018; 29 Carbognin, Pilotto, Milella (R19) 2015; 10 Paver, Cooper, Colebatch (R18) 2021; 53 Jardim (2024041119300865000_12.4.e008592.12) 2023; 11 2024041119300865000_12.4.e008592.27 2024041119300865000_12.4.e008592.29 Kim (2024041119300865000_12.4.e008592.6) 2017; 8 Terra (2024041119300865000_12.4.e008592.35) 2019; 74 Carbognin (2024041119300865000_12.4.e008592.19) 2015; 10 Vokes (2024041119300865000_12.4.e008592.28) 2018; 29 Lacour (2024041119300865000_12.4.e008592.38) 2018; 29 Bai (2024041119300865000_12.4.e008592.11) 2017; 8 2024041119300865000_12.4.e008592.34 2024041119300865000_12.4.e008592.13 2024041119300865000_12.4.e008592.30 2024041119300865000_12.4.e008592.10 2024041119300865000_12.4.e008592.32 Sheng (2024041119300865000_12.4.e008592.9) 2016; 6 2024041119300865000_12.4.e008592.33 Hack (2024041119300865000_12.4.e008592.43) 2020; 11 2024041119300865000_12.4.e008592.2 Nishio (2024041119300865000_12.4.e008592.31) 2021; 16 2024041119300865000_12.4.e008592.1 2024041119300865000_12.4.e008592.16 2024041119300865000_12.4.e008592.17 2024041119300865000_12.4.e008592.39 2024041119300865000_12.4.e008592.18 Casadevall (2024041119300865000_12.4.e008592.15) 2017; 18 2024041119300865000_12.4.e008592.4 2024041119300865000_12.4.e008592.3 Liang (2024041119300865000_12.4.e008592.14) 2009; 276 2024041119300865000_12.4.e008592.5 2024041119300865000_12.4.e008592.40 Gowrishankar (2024041119300865000_12.4.e008592.36) 2015; 10 2024041119300865000_12.4.e008592.23 Gandhi (2024041119300865000_12.4.e008592.24) 2018; 78 2024041119300865000_12.4.e008592.25 2024041119300865000_12.4.e008592.26 2024041119300865000_12.4.e008592.41 Choe (2024041119300865000_12.4.e008592.7) 2019; 136 Zens (2024041119300865000_12.4.e008592.8) 2022; 35 2024041119300865000_12.4.e008592.20 2024041119300865000_12.4.e008592.42 2024041119300865000_12.4.e008592.21 Frank (2024041119300865000_12.4.e008592.37) 2020; 149 2024041119300865000_12.4.e008592.22 |
References_xml | – volume: 29 start-page: 959 year: 2018 ident: R28 article-title: Nivolumab versus Docetaxel in previously treated advanced non-small-cell lung cancer (Checkmate 017 and Checkmate 057): 3-year update and outcomes in patients with liver metastases publication-title: Ann Oncol doi: 10.1093/annonc/mdy041 contributor: fullname: Felip – volume: 37 start-page: 537 year: 2019 ident: R4 article-title: Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non–small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater publication-title: J Clin Oncol doi: 10.1200/JCO.18.00149 contributor: fullname: Robinson – volume: 27 start-page: 147 year: 2016 ident: R34 article-title: Comparative study of the PD-L1 status between surgically Resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies publication-title: Ann Oncol doi: 10.1093/annonc/mdv489 contributor: fullname: Bence – volume: 11 year: 2020 ident: R43 article-title: Augmenting anticancer immunity through combined targeting of angiogenic and PD-1/PD-L1 pathways: challenges and opportunities publication-title: Front Immunol doi: 10.3389/fimmu.2020.598877 contributor: fullname: Wang – volume: 144 start-page: 1219 year: 2018 ident: R41 article-title: Chemotherapy treatment is associated with altered PD-L1 expression in lung cancer patients publication-title: J Cancer Res Clin Oncol doi: 10.1007/s00432-018-2642-4 contributor: fullname: Téglási – volume: 15 start-page: 405 year: 2015 ident: R10 article-title: Type I interferons in anticancer immunity publication-title: Nat Rev Immunol doi: 10.1038/nri3845 contributor: fullname: Kepp – volume: 10 year: 2015 ident: R19 article-title: Differential activity of Nivolumab, Pembrolizumab and Mpdl3280A according to the tumor expression of programmed death-Ligand-1 (PD-L1): sensitivity analysis of trials in Melanoma publication-title: PLoS One doi: 10.1371/journal.pone.0130142 contributor: fullname: Milella – volume: 22 start-page: 198 year: 2021 ident: R27 article-title: First-line Nivolumab plus Ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (Checkmate 9La): an international, randomised, open-label, phase 3 trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(20)30641-0 contributor: fullname: Cobo – volume: 10 year: 2015 ident: R36 article-title: Inducible but not constitutive expression of PD-L1 in human Melanoma cells is dependent on activation of NF-ΚB publication-title: PLoS One doi: 10.1371/journal.pone.0123410 contributor: fullname: Gallagher – volume: 16 start-page: 653 year: 2021 ident: R31 article-title: Atezolizumab plus chemotherapy for first-line treatment of Nonsquamous NSCLC: results from the randomized phase 3 Impower132 trial publication-title: J Thorac Oncol doi: 10.1016/j.jtho.2020.11.025 contributor: fullname: West – volume: 6 year: 2016 ident: R9 article-title: Expression of programmed death Ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer publication-title: Sci Rep doi: 10.1038/srep20090 contributor: fullname: Yu – volume: 376 start-page: 2415 year: 2017 ident: R26 article-title: First-line Nivolumab in stage IV or recurrent non-small-cell lung cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1613493 contributor: fullname: Paz-Ares – volume: 20 start-page: 25 year: 2020 ident: R42 article-title: Tumour-intrinsic resistance to immune checkpoint blockade publication-title: Nat Rev Immunol doi: 10.1038/s41577-019-0218-4 contributor: fullname: Ribas – volume: 11 year: 2023 ident: R12 article-title: PD-L1 gene amplification and focality: relationship with protein expression publication-title: J Immunother Cancer doi: 10.1136/jitc-2022-006311 contributor: fullname: Elvin – volume: 8 start-page: 110693 year: 2017 ident: R11 article-title: Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade publication-title: Oncotarget doi: 10.18632/oncotarget.22690 contributor: fullname: Li – volume: 377 start-page: 1919 year: 2017 ident: R29 article-title: Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1709937 contributor: fullname: Daniel – volume: 112 start-page: 1501 year: 2015 ident: R39 article-title: IFN-Γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer publication-title: Br J Cancer doi: 10.1038/bjc.2015.101 contributor: fullname: Hamanishi – volume: 35 start-page: 1848 year: 2022 ident: R8 article-title: The effect of neoadjuvant therapy on PD-L1 expression and Cd8+Lymphocyte density in non-small cell lung cancer publication-title: Mod Pathol doi: 10.1038/s41379-022-01139-y contributor: fullname: Scherz – volume: 112 start-page: 200 year: 2017 ident: R17 article-title: PD-L1 expression in advanced NSCLC: insights into risk stratification and treatment selection from a systematic literature review publication-title: Lung Cancer doi: 10.1016/j.lungcan.2017.08.005 contributor: fullname: Ballas – volume: 38 start-page: 1505 year: 2020 ident: R3 article-title: Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer publication-title: J Clin Oncol doi: 10.1200/JCO.19.03136 contributor: fullname: Speranza – volume: 134 start-page: 79 year: 2019 ident: R33 article-title: Heterogeneity of PD-L1 expression in non-small cell lung cancer: implications for specimen sampling in predicting treatment response publication-title: Lung Cancer doi: 10.1016/j.lungcan.2019.06.005 contributor: fullname: Davies – volume: 38 start-page: 3789 year: 2018 ident: R32 article-title: Heterogeneity of PD-L1 expression and relationship with biology of NSCLC publication-title: Anticancer Res doi: 10.21873/anticanres.12662 contributor: fullname: Martini – volume: 149 start-page: 23 year: 2020 ident: R37 article-title: Re-biopsy after first line treatment in advanced NSCLC can reveal changes in PD-L1 expression publication-title: Lung Cancer doi: 10.1016/j.lungcan.2020.08.020 contributor: fullname: Høegholm – volume: 74 start-page: 364 year: 2019 ident: R35 article-title: Heterogeneity of programmed death-ligand 1 expression in thymic epithelial tumours between initial specimen and synchronous or metachronous metastases or recurrences publication-title: Histopathology doi: 10.1111/his.13750 contributor: fullname: Vrana – volume: 17 start-page: e542 year: 2016 ident: R5 article-title: Predictive biomarkers for checkpoint inhibitor-based immunotherapy publication-title: Lancet Oncol doi: 10.1016/S1470-2045(16)30406-5 contributor: fullname: Atkins – volume: 50 start-page: 1361 year: 2014 ident: R13 article-title: Programmed cell death-ligand 1 expression in surgically Resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes publication-title: Eur J Cancer doi: 10.1016/j.ejca.2014.01.018 contributor: fullname: Chang – volume: 379 start-page: 2040 year: 2018 ident: R25 article-title: Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1810865 contributor: fullname: Vicente – volume: 71 start-page: 209 year: 2021 ident: R1 article-title: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries publication-title: CA Cancer J Clin doi: 10.3322/caac.21660 contributor: fullname: Siegel – volume: 378 start-page: 2288 year: 2018 ident: R30 article-title: Atezolizumab for first-line treatment of metastatic Nonsquamous NSCLC publication-title: N Engl J Med doi: 10.1056/NEJMoa1716948 contributor: fullname: Cappuzzo – volume: 398 start-page: 1344 year: 2021 ident: R22 article-title: Adjuvant atezolizumab after adjuvant chemotherapy in Resected stage IB–IIIA non-small-cell lung cancer (Impower010): a randomised, Multicentre, open-label, phase 3 trial publication-title: Lancet doi: 10.1016/S0140-6736(21)02098-5 contributor: fullname: Zhou – volume: 124 start-page: 687 year: 2014 ident: R40 article-title: Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice publication-title: J Clin Invest doi: 10.1172/JCI67313 contributor: fullname: Burnette – volume: 8 start-page: 107630 year: 2017 ident: R6 article-title: Changes in PD-L1 expression according to tumor infiltrating lymphocytes of acquired EGFR-TKI resistant EGFR-mutant non-small-cell lung cancer publication-title: Oncotarget doi: 10.18632/oncotarget.22582 contributor: fullname: Kim – volume: 276 start-page: 47 year: 2009 ident: R14 article-title: Nimesulide inhibits IFN-gamma-induced programmed Death-1-ligand 1 surface expression in breast cancer cells by COX-2 and Pge2 independent mechanisms publication-title: Cancer Lett doi: 10.1016/j.canlet.2008.10.028 contributor: fullname: Fu – volume: 136 start-page: 30 year: 2019 ident: R7 article-title: Dynamic changes in PD-L1 expression and Cd8+ T cell infiltration in non-small cell lung cancer following chemoradiation therapy publication-title: Lung Cancer doi: 10.1016/j.lungcan.2019.07.027 contributor: fullname: Kim – volume: 53 start-page: 141 year: 2021 ident: R18 article-title: Programmed death Ligand-1 (PD-L1) as a predictive marker for Immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation publication-title: Pathology doi: 10.1016/j.pathol.2020.10.007 contributor: fullname: Colebatch – volume: 375 start-page: 1823 year: 2016 ident: R20 article-title: Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1606774 contributor: fullname: Robinson – volume: 18 start-page: 682 year: 2017 ident: R15 article-title: Heterogeneity of tumor and immune cell PD-L1 expression and lymphocyte counts in surgical NSCLC samples publication-title: Clin Lung Cancer doi: 10.1016/j.cllc.2017.04.014 contributor: fullname: Taus – volume: 379 start-page: 2342 year: 2018 ident: R23 article-title: Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC publication-title: N Engl J Med doi: 10.1056/NEJMoa1809697 contributor: fullname: Daniel – volume: 29 year: 2018 ident: R38 article-title: The need of re-biopsy: increase in PD-L1 expression from initial stage to recurrence of non-small cell lung cancer publication-title: Annals of Oncology doi: 10.1093/annonc/mdy292.040 contributor: fullname: Rulle – volume: 11 start-page: 4982 year: 2019 ident: R16 article-title: Inter-tumor heterogeneity of PD-L1 expression in non-small cell lung cancer publication-title: J Thorac Dis doi: 10.21037/jtd.2019.12.24 contributor: fullname: Morooka – volume: 17 start-page: 1497 year: 2016 ident: R21 article-title: Carboplatin and Pemetrexed with or without Pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study publication-title: Lancet Oncol doi: 10.1016/S1470-2045(16)30498-3 contributor: fullname: Borghaei – volume: 78 year: 2018 ident: R24 article-title: Abstract Ct075: KEYNOTE-189: randomized, double-blind, phase 3 study of Pembrolizumab (Pembro) or placebo plus Pemetrexed (Pem) and platinum as first-line therapy for metastatic NSCLC publication-title: Cancer Research doi: 10.1158/1538-7445.AM2018-CT075 contributor: fullname: Gadgeel – volume: 10 year: 2015 ident: 2024041119300865000_12.4.e008592.36 article-title: Inducible but not constitutive expression of PD-L1 in human Melanoma cells is dependent on activation of NF-ΚB publication-title: PLoS One doi: 10.1371/journal.pone.0123410 contributor: fullname: Gowrishankar – volume: 29 start-page: 959 year: 2018 ident: 2024041119300865000_12.4.e008592.28 article-title: Nivolumab versus Docetaxel in previously treated advanced non-small-cell lung cancer (Checkmate 017 and Checkmate 057): 3-year update and outcomes in patients with liver metastases publication-title: Ann Oncol doi: 10.1093/annonc/mdy041 contributor: fullname: Vokes – ident: 2024041119300865000_12.4.e008592.41 doi: 10.1007/s00432-018-2642-4 – volume: 149 start-page: 23 year: 2020 ident: 2024041119300865000_12.4.e008592.37 article-title: Re-biopsy after first line treatment in advanced NSCLC can reveal changes in PD-L1 expression publication-title: Lung Cancer doi: 10.1016/j.lungcan.2020.08.020 contributor: fullname: Frank – volume: 276 start-page: 47 year: 2009 ident: 2024041119300865000_12.4.e008592.14 article-title: Nimesulide inhibits IFN-gamma-induced programmed Death-1-ligand 1 surface expression in breast cancer cells by COX-2 and Pge2 independent mechanisms publication-title: Cancer Lett doi: 10.1016/j.canlet.2008.10.028 contributor: fullname: Liang – ident: 2024041119300865000_12.4.e008592.17 doi: 10.1016/j.lungcan.2017.08.005 – ident: 2024041119300865000_12.4.e008592.3 doi: 10.1200/JCO.19.03136 – volume: 18 start-page: 682 year: 2017 ident: 2024041119300865000_12.4.e008592.15 article-title: Heterogeneity of tumor and immune cell PD-L1 expression and lymphocyte counts in surgical NSCLC samples publication-title: Clin Lung Cancer doi: 10.1016/j.cllc.2017.04.014 contributor: fullname: Casadevall – ident: 2024041119300865000_12.4.e008592.13 doi: 10.1016/j.ejca.2014.01.018 – ident: 2024041119300865000_12.4.e008592.20 doi: 10.1056/NEJMoa1606774 – volume: 16 start-page: 653 year: 2021 ident: 2024041119300865000_12.4.e008592.31 article-title: Atezolizumab plus chemotherapy for first-line treatment of Nonsquamous NSCLC: results from the randomized phase 3 Impower132 trial publication-title: J Thorac Oncol doi: 10.1016/j.jtho.2020.11.025 contributor: fullname: Nishio – ident: 2024041119300865000_12.4.e008592.16 doi: 10.21037/jtd.2019.12.24 – volume: 29 year: 2018 ident: 2024041119300865000_12.4.e008592.38 article-title: The need of re-biopsy: increase in PD-L1 expression from initial stage to recurrence of non-small cell lung cancer publication-title: Annals of Oncology doi: 10.1093/annonc/mdy292.040 contributor: fullname: Lacour – volume: 8 start-page: 110693 year: 2017 ident: 2024041119300865000_12.4.e008592.11 article-title: Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade publication-title: Oncotarget doi: 10.18632/oncotarget.22690 contributor: fullname: Bai – ident: 2024041119300865000_12.4.e008592.4 doi: 10.1200/JCO.18.00149 – volume: 10 year: 2015 ident: 2024041119300865000_12.4.e008592.19 article-title: Differential activity of Nivolumab, Pembrolizumab and Mpdl3280A according to the tumor expression of programmed death-Ligand-1 (PD-L1): sensitivity analysis of trials in Melanoma publication-title: PLoS One doi: 10.1371/journal.pone.0130142 contributor: fullname: Carbognin – volume: 8 start-page: 107630 year: 2017 ident: 2024041119300865000_12.4.e008592.6 article-title: Changes in PD-L1 expression according to tumor infiltrating lymphocytes of acquired EGFR-TKI resistant EGFR-mutant non-small-cell lung cancer publication-title: Oncotarget doi: 10.18632/oncotarget.22582 contributor: fullname: Kim – ident: 2024041119300865000_12.4.e008592.25 doi: 10.1056/NEJMoa1810865 – ident: 2024041119300865000_12.4.e008592.29 doi: 10.1056/NEJMoa1709937 – volume: 11 year: 2020 ident: 2024041119300865000_12.4.e008592.43 article-title: Augmenting anticancer immunity through combined targeting of angiogenic and PD-1/PD-L1 pathways: challenges and opportunities publication-title: Front Immunol doi: 10.3389/fimmu.2020.598877 contributor: fullname: Hack – ident: 2024041119300865000_12.4.e008592.10 doi: 10.1038/nri3845 – volume: 78 year: 2018 ident: 2024041119300865000_12.4.e008592.24 article-title: Abstract Ct075: KEYNOTE-189: randomized, double-blind, phase 3 study of Pembrolizumab (Pembro) or placebo plus Pemetrexed (Pem) and platinum as first-line therapy for metastatic NSCLC publication-title: Cancer Research doi: 10.1158/1538-7445.AM2018-CT075 contributor: fullname: Gandhi – ident: 2024041119300865000_12.4.e008592.34 doi: 10.1093/annonc/mdv489 – volume: 35 start-page: 1848 year: 2022 ident: 2024041119300865000_12.4.e008592.8 article-title: The effect of neoadjuvant therapy on PD-L1 expression and Cd8+Lymphocyte density in non-small cell lung cancer publication-title: Mod Pathol doi: 10.1038/s41379-022-01139-y contributor: fullname: Zens – ident: 2024041119300865000_12.4.e008592.23 doi: 10.1056/NEJMoa1809697 – ident: 2024041119300865000_12.4.e008592.27 doi: 10.1016/S1470-2045(20)30641-0 – ident: 2024041119300865000_12.4.e008592.30 doi: 10.1056/NEJMoa1716948 – volume: 11 year: 2023 ident: 2024041119300865000_12.4.e008592.12 article-title: PD-L1 gene amplification and focality: relationship with protein expression publication-title: J Immunother Cancer doi: 10.1136/jitc-2022-006311 contributor: fullname: Jardim – ident: 2024041119300865000_12.4.e008592.40 doi: 10.1172/JCI67313 – volume: 136 start-page: 30 year: 2019 ident: 2024041119300865000_12.4.e008592.7 article-title: Dynamic changes in PD-L1 expression and Cd8+ T cell infiltration in non-small cell lung cancer following chemoradiation therapy publication-title: Lung Cancer doi: 10.1016/j.lungcan.2019.07.027 contributor: fullname: Choe – ident: 2024041119300865000_12.4.e008592.33 doi: 10.1016/j.lungcan.2019.06.005 – volume: 6 year: 2016 ident: 2024041119300865000_12.4.e008592.9 article-title: Expression of programmed death Ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer publication-title: Sci Rep doi: 10.1038/srep20090 contributor: fullname: Sheng – ident: 2024041119300865000_12.4.e008592.5 doi: 10.1016/S1470-2045(16)30406-5 – volume: 74 start-page: 364 year: 2019 ident: 2024041119300865000_12.4.e008592.35 article-title: Heterogeneity of programmed death-ligand 1 expression in thymic epithelial tumours between initial specimen and synchronous or metachronous metastases or recurrences publication-title: Histopathology doi: 10.1111/his.13750 contributor: fullname: Terra – ident: 2024041119300865000_12.4.e008592.22 doi: 10.1016/S0140-6736(21)02098-5 – ident: 2024041119300865000_12.4.e008592.1 doi: 10.3322/caac.21660 – ident: 2024041119300865000_12.4.e008592.18 doi: 10.1016/j.pathol.2020.10.007 – ident: 2024041119300865000_12.4.e008592.21 doi: 10.1016/S1470-2045(16)30498-3 – ident: 2024041119300865000_12.4.e008592.2 – ident: 2024041119300865000_12.4.e008592.42 doi: 10.1038/s41577-019-0218-4 – ident: 2024041119300865000_12.4.e008592.32 doi: 10.21873/anticanres.12662 – ident: 2024041119300865000_12.4.e008592.26 doi: 10.1056/NEJMoa1613493 – ident: 2024041119300865000_12.4.e008592.39 doi: 10.1038/bjc.2015.101 |
SSID | ssj0001033888 |
Score | 2.3433664 |
Snippet | BackgroundThe use and approval of immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) depends on PD-L1 expression in the tumor... The use and approval of immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) depends on PD-L1 expression in the tumor tissue.... Background The use and approval of immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) depends on PD-L1 expression in the... BACKGROUNDThe use and approval of immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) depends on PD-L1 expression in the tumor... Background The use and approval of immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) depends on PD-L1 expression in the... |
SourceID | doaj proquest crossref pubmed bmj |
SourceType | Open Website Aggregation Database Index Database Publisher |
StartPage | e008592 |
SubjectTerms | B7-H1 Antigen - metabolism Biomarker Biopsy Carcinoma, Non-Small-Cell Lung - pathology Clinical/translational cancer immunotherapy FDA approval Histology Humans Immune Checkpoint Inhibitor Lung Cancer Lung Neoplasms - pathology Lymphatic system Metastasis Mutation Neoplasm Recurrence, Local Oncology Patients Recurrence Retrospective Studies Small Cell Lung Carcinoma Surgery Tumors |
SummonAdditionalLinks | – databaseName: BMJ Open Access Journals dbid: 9YT link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3dS8MwEA-iIL6I384vIuiDD8Fk-Wj7qFNRmSK4gT6VpElhA7vhNvDP967tNhQVH9teQ3qX9H6XS35HyEncVD4S2jHTzC1T4COZk8EzHbRVKljuOR4Ufng0t111_6Jf5jQ53zL4Qprzfm-cMSzyzRAeJPC7XdLaJMiTn7x25uspHIKtOJ5mIn94cYUsy9ggP4oAR-Le-l9cUcnY_zvMLN3NzRpZrXEivagMu04WQrFBlh_qTPgmuWsPsNLQxGNVK2prahE6yOnTFWsLGj7qHa4F7RW0Zk8dUVx2pXh-ZTgKnj4-t9qtLdK9ue60blldFoE5mGBjJprGx5Y73BlqADBJLSOvARYpCNaacWazLM-4CSESwQNCsCDntfAgr62Qudwmi8WgCLuESp2FXEY8ccjfKyLrufLYtFFWJNY3yCnoKa2H9SgtIwZpUlRtiqpNK9U2yNlUk-mwYsn4Q_YSVT2TQ37r8gYYPa2nSxo5qZE6LOQQwHLuwG5Ymyaz3vjEZ9DIwdRQ895JpBtIpFS8QY5nj2G6YA7EFmEwQRkZV8ndBtmpDDzryXR07P3zq_fJClyV-3iEOCCL4_dJOASIMnZH5dj8BK062Wo priority: 102 providerName: BMJ Publishing Group Ltd – databaseName: AUTh Library subscriptions: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9NAEB7RVEJcEG8CBS0SHDisuut92DkhGloVlEYVUKk3a1-uWgk7NInEz2fG3iTiQK_2aL3-9jWv_QbgfVXoWErjuS0axzWekdyrFLlJxmmdnIiCLgqfze3phf52aS6zw22Z0yo3e2K_UccukI_8UNFdcrS-tfi0-M2pahRFV3MJjT3YL4i5aQT7R8fz8-87L4tAE6yqNvFJZQ9vrleBU81wTtoGRUD3_K-bf06lnrz__xpnf_KcPIKHWWVkn4cxfgz3UvsE7p_loPhT-DrrqOjQOlKBK-YyywjrGnb-hc8kS39ysmvLrluWiVSXjDywjK6yLJYpsvmP6Wz6DC5Ojn9OT3mukMA9rrUVl4WNlROekkQt6k7KqDIa1JA02m1FFVwITRA2pVKmiMqCQ7loZER546Rq1HMYtV2bXgJTJqRGlWLiicpXli4KHalpq52cuDiGD4hTnWf4su6NB2VrwrMmPOsBzzF83CBZLwbCjDtkjwjqrRxRXfcPuturOq-cuvTKEItYatCWFcJXti9TE1y0cRIDNnKwGahd73azZQzvtq9x5VA4xLWpW5OMqoY47xheDAO87YnCryAK8tXdjb-GB_g7fSaPlAcwWt2u0xtUUlb-bZ6JfwGMzOEz priority: 102 providerName: ProQuest – databaseName: Scholars Portal Journals: Open Access dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LT9wwELYqkKpeUFta2BYqI8GhBxc7fiQ5INRuixa0u0KiK3GL7NhBIJrQfUj033cm8S6qBJx6TSaO840nM-PHN4TsZ4nyqdCOmaSyTIGPZE4Gz3TQVqlgued4UHg0NoOJOrvUlw_HoyOAs0dTO6wnNZnefrn__ecYDP4oViQ5vLmelwzLgDMMIHL4Ia8nSkoc46MY7LczLhzSsSxbrlU-8iD4F_fr5h8P1RL5Px19tl7o5DXZiOEj_drp-w15Eeq35OUoLpBvktNhgwWIFh6LXVEbGUdoU9Hz72woaLiPG19rel3TSKo6ozgbS_FYy90seDq-6A_778jk5MfP_oDFagnMgd3NmUiMzyx3uGHUQBwltUy9hmhJQQ6XZKUty6rkJoRUBA-BgwU5r4UHeW2FrOR7slY3ddgmVOoyVDLluUNaX5Faz5XHpo2yIre-Rw4Ap2KprKJNJKQpEM8C8Sw6PHvk8xLJ4q4jz3hG9htCvZJD2uv2QjO9KqIVFamTGhnFQgV5LecuM23JmtJ643NfQiM7S0U99E4iC0EupeI9sre6DVaESyO2Ds0CZWTWrfn2yFan4FVPJLwFUBAf_kcPP5JX8NHt3h8hdsjafLoIuxDWzN2ndrT-BZgB7_c priority: 102 providerName: Scholars Portal |
Title | Longitudinal analysis of PD-L1 expression in patients with relapsed NSCLC |
URI | http://dx.doi.org/10.1136/jitc-2023-008592 https://www.ncbi.nlm.nih.gov/pubmed/38604811 https://www.proquest.com/docview/3041593340 https://search.proquest.com/docview/3038428706 https://doaj.org/article/7b357905ef25400b8600961cad6d9dc2 |
Volume | 12 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEB7ygNJLadNH3KaLCs2hBxFp9bB9TLYJSVgvIU3K9mQkS4YE6g3dXcjPz4zt3aaHtpdcbLAHe_yNZM1opG8APmdDHVJpPLfD2nGNYyT3KgZuonFaRyeCoI3CxcSeXuvzqZk-KvVFa8I6euAOuIPUK0MkUrHGUEYIn9m2Sknlgg15qLq_r3wcTLWzKwJDryxb5SWVPbi9WVScaoVz8jIo87npf97-MRq1pP1_9zTbEefkJbzoXUV22Kn4CjZiswPPij4Z_hrOxjMqNrQMVNiKuZ5dhM1qdvGVjyWL9_0i14bdNKwnUJ0zmnlltIXlbh4Dm3wbjUdv4Prk-Gp0yvvKCNxjH1twObQhc8LT4lCLPpMyKg0GPSON8dowq1xV1ZWwMaYyBnQSHMoFIwPKGydVrd7CVjNr4i4wZapYq1Tknih8ZeqC0IEebbWTuQsJ7CNOZd-y52UbNChbEp4l4Vl2eCbwZYVkedcRZfxD9oigXssRxXV7AQ1f9oYv_2f4BPZWhvqtnSLGgVwpLRL4tL6NPYbSIK6JsyXJqKzL7ybwrjPwWhOFb0EU5Pun0PADPMePbtf5SLkHW4tfy_gRXZiFH8BmOk3xmP-4GsD24agovuP56HhycTloWzIeC509AK0s7a4 |
link.rule.ids | 315,786,790,870,2113,2232,12077,21409,24339,27946,27947,31743,31744,33768,33769,43334,43829,55693,55694,74091,74648 |
linkProvider | Directory of Open Access Journals |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LbxMxELZokYALKq8SaMFIcOBg1Y4fuzmhEqhS2ERItFJull-LWond0CQSP5-ZXScRh_a6Htne8dj-5uEZQt6XQxULoT0zw9oxBXck8zJFppN2SiXHI8eHwtOZmVyqb3M9zwa3ZQ6r3JyJ3UEd24A28hOJb8lB-1b80-IPw6pR6F3NJTT2yH0loQ3kuZgXOxsLBwWsLDfeSWlOrq9WgWHFcIZYA_2fe_739X93Upe6_3a82d07ZwfkcQaM9LRf4SfkXmqekgfT7BJ_Rs6rFksOrSOWt6Iu5xihbU1_fGGVoOlvDnVt6FVDcxrVJUX7K8WHLItlinT2c1yNn5PLs68X4wnL9RGYh522YmJoYum4xxBRA8hJallEDfhIgdY2LIMLoQ7cpFSIFAEqOKCLWkSg107IWr4g-03bpJeESh1SLQs-8pjIVxQuchWxa6OcGLk4IB-ATzbL99J2qoM0FvlpkZ-25-eAfNxw0i76dBl30H5GVm_pMNF196G9-WXzvrGFlxpziKUaNFnOfWm6IjXBRRNHMUAnR5uF2s1uJysD8m7bDPsGnSGuSe0aaWTZe3kH5LBf4O1MJIwCXBCv7u78LXk4uZhWtjqffX9NHsGvdTE9QhyR_dXNOh0DXFn5N51M_gNdP-K4 |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LbxMxELZokSouiDeBAkaCAwcrdvzanBCkRC2kUSWolJvl16JWYjc0icTPZ2bXScSBXndHXu_nGXteniHkXTVSyQodmBnVnik4I1mQOTGdtVcqe544XhQ-n5vTS_V1oRcl_2lV0iq3e2K3Uac2oo98KPEuOVjfig_rkhZxcTL9uPzNsIMURlpLO40DcteC0YJCahd272_hYIxV1TZSKc3w-modGXYPZ6h3YCz0IPy6_ud86sr4_1_37M6g6QNyvyiP9FO_2g_Jndw8IkfnJTz-mJzNWmw_tEnY6or6Um-EtjW9OGEzQfOfkvba0KuGlpKqK4q-WIqXWparnOj8-2Q2eUIup19-TE5Z6ZXAAkjdmomRSZXnAdNFDWhRUkubNOhKCiy4URV9jHXkJmcrcgK1wQNd0iIBvfZC1vIpOWzaJj8nVOqYa2n5OGBRX2F94irh0EZ5MfZpQN4DTq7w-sp1ZoQ0DvF0iKfr8RyQD1sk3bIvnXEL7WeEekeHRa-7B-3NT1dkyNkgNdYTyzVYtZyHynQNa6JPJo1ThEGOtwu1n92ebwbk7e41yBAGRnyT2w3SyKqP-A7Is36BdzOR8BVAQby4ffA35AjY0c3O5t9eknvwZ116jxDH5HB9s8mvQHNZh9cdS_4FN2Lm7Q |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Longitudinal+analysis+of+PD-L1+expression+in+patients+with+relapsed+NSCLC&rft.jtitle=Journal+for+immunotherapy+of+cancer&rft.au=Florian+Posch&rft.au=Luka+Br%C4%8Di%C4%87&rft.au=Gudrun+Absenger&rft.au=Verena+Schlintl&rft.date=2024-04-11&rft.pub=BMJ+Publishing+Group&rft.eissn=2051-1426&rft.volume=12&rft.issue=4&rft_id=info:doi/10.1136%2Fjitc-2023-008592&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_7b357905ef25400b8600961cad6d9dc2 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2051-1426&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2051-1426&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2051-1426&client=summon |